From: Aspergillus fumigatus during COPD exacerbation: a pair-matched retrospective study
Aspergillus colonization, n = 23 | Control, n = 69 | p value | |
---|---|---|---|
Admitted in ICU | 4 (17.4%) | 11 (15.9%) | 1.000 |
Machined ventilation | 3 (13.0%) | 9 (13.0%) | 0.906 |
Antibiotics | 21 (95.5%) | 66 (95.7%) | 1.000 |
More than 1 class | 52.2% | 21.7% | 0.006 |
Duration of treatment (days) | 13 ± 5 | 10 ± 4 | 0.003 |
Corticosteroid use | 17 (77.3%) | 42 (60.9%) | 0.204 |
Systemic only | 0 | 2 (2.90%) | 1.000 |
Inhalation only | 8 (34.8%) | 20 (29.0%) | 0.601 |
Dose of usage | |||
Budesonide (inhaled,≥40 mg) | 30.4% | 5.8% | 0.002 |
Methylprednisolone (iv,≥120 mg) | 39.1% | 31.9% | 0.524 |
Bronchodilators (aerosol inhalation) | 21 (91.3%) | 57 (82.6%) | 0.505 |
Ipratropium Bromide (mg) | 16.3 ± 11.6 | 14.8 ± 8.2 | 0.631 |
Salbutamol (mg) | 115 ± 98 | 83 ± 53 | 0.308 |
Remission time (days) | 11 ± 4 | 7 ± 4 | 0.001 |
Duration of hospitalization (days) | 15 ± 5 | 12 ± 4 | 0.011 |